Search
News & Events
The Kids Research Institute Australia researcher awarded support fundingA Kids Research Institute Australia researcher has been awarded $10,000 from the New Independent Researcher Infrastructure Support (NIRIS) award.
News & Events
Celebrating 20 years of meningitis awarenessAustralian charity celebrates 20 years of providing meningitis awareness and marks World Meningitis Day with footy star
News & Events
Caesarean link to respiratory infections in babiesCaesarean link to respiratory infections in babies
News & Events
Perth trial begins on investigational Golden Staph vaccinePerth researchers are calling for volunteers to help test an investigational vaccine against Staphylococcus aureus (golden staph).
News & Events
Volunteers needed to trial new vaccine against dengue feverPerth researchers are about to trial a new vaccine that aims to protect against all four strains of the potentially devastating Dengue Fever.
News & Events
Infections leave life-long scarsHigh rates of recurrent infection are a major risk to the health of Aboriginal children and are comparable to those of third world countries.
Research
STopping Acute Rheumatic Fever Infections to Strengthen Health (STARFISH)STopping Acute Rheumatic Fever Infections to Strengthen Health (STARFISH) brings together a diverse and multidisciplinary research team to investigate the most effective environmental health initiatives (EHIs) aimed at reducing Strep A infections and prevent Acute Rheumatic Fever (ARF).
Research
Prevention of rheumatic heart disease in New Zealand: High-dose subcutaneous benzathine penicillin is cost-saving compared with traditional intramuscular injectionsAcute rheumatic fever is a preventable condition that can lead to chronic illness and early death. Standard prevention with 4-weekly intramuscular (IM) benzathine penicillin G (BPG) injections for ≥10 years may be associated with poor adherence. High-dose 10-weekly subcutaneous penicillin injections (SCIP) may improve adherence by reducing injection frequency.
Research
Nirsevimab immunisation of infants and respiratory syncytial virus (RSV)-associated hospitalisations, Western Australia, 2024: a population-based analysisChristopher Peter Hannah Blyth Richmond Moore MBBS (Hons) DCH FRACP FRCPA PhD MBBS MRCP(UK) FRACP OAM BSc (Hons) GradDipClinEpi PhD Centre Head,
Research
Predicting immune protection against outcomes of infectious disease from population-level effectiveness data with application to COVID-19Quantifying the extent to which previous infections and vaccinations confer protection against future infection or disease outcomes is critical to managing the transmission and consequences of infectious diseases. We present a general statistical model for predicting the strength of protection conferred by different immunising exposures (numbers, types, and strains of both vaccines and infections), against multiple outcomes of interest, whilst accounting for immune waning.